Back

Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?

Cardiovascular Research

8 July 2020
Organised by: Logo
Read full article
ESC Journals

Contributors

Francesco Paneni
Francesco Paneni

Author

Center for Translational and Experimental Cardiology (CTEC) Zurich , Switzerland

Sebastiano Sciarretta
Sebastiano Sciarretta

Author

Sarah Costantino
Sarah Costantino

Author

You may be interested in
thumbnail
Congress Presentation
Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence
29 June 2021
thumbnail
Congress Session
Advances in medical therapy in heart failure
20 May 2025
thumbnail
Congress Presentation
The effect of one year treatment with GLP1-RA, SGLT2i and their combination on plasma levels of oxidative and antioxidative biomarkers
27 August 2021
thumbnail
Congress Presentation
Factors associated with oral SGLT2 inhibitor use and prognosis in elderly heart failure patients
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources